The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
The Journal for ImmunoTherapy of Cancer (JITC) received its first impact factor of 8.374 on June 26, 2018. JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
Published in the annual Journal Citation Reports (JCR), the impact factor is a calculation determined on the number of 2017 citations accumulated for JITC manuscripts published in 2015 and 2016. Other journal metrics for JITC can be found on the journal website.
JITC is indexed in six major indexing sources, including PubMed, PubMed Central, MEDLINE, the Directory of Open Access journals, Scopus, and Clarivate Analytics' Science Citation Index Expanded (SCIE). The SCIE is part of the robust Web and Science collection, the world’s largest compilation of research data, books, journals, proceedings, publications and patents. Learn more by reviewing these frequently asked questions.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 60 percent discount on processing fees for all JITC articles submitted and accepted in 2019. To take advantage of this SITC member benefit, authors must contact JITC Managing Editor Andrea Kunz at JITCEditor@sitcancer.org or 1-414-271-2456 prior to submission to obtain a discount code and instructions.
Basic Tumor Immunology
Clinical Trials Monitor
Clinical/Translational Cancer Immunotherapy
Guidelines and Consensus Statements
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Immune checkpoints play important roles in immune regulation, and blocking immune checkpoints on the cell membrane is a promising strategy in the treatment of cancer. Based on this, monoclonal antibodies are having much rapid development, such as those against CTLA-4 (cytotoxic T lymphocyte antigen 4) and PD-1 (programmed cell death protein 1).But the cost of preparation of monoclonal antibodies is too high and the therapeutic effect is still under restrictions. Recently, a series of soluble immune checkpoints have been found such as sCTLA-4 (soluble CTLA-4) and sPD-1 (soluble PD-1). They are functional parts of membrane immune checkpoints produced in different ways and can be secreted by immune cells...
Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining olaparib with immunotherapy in prostate cancer patients both with and without somatic BRCA mutations...
Hello Anyone can share their experience with sarcoidosis flare after treatment with a PD-1 inhibitor? Thank you ------------------------------ Priscila Goncalves Associate Director Center for Novel Cancer Therapies Northwell Health - Monter Cancer Center ...
The New York Academy of Sciences is proud to present three events this May that we think would be of outstanding interest to the community-- Targeting Tumor Heterogeneity , Cancer Metabolism and Signaling , and Frontiers in Cancer ...
The Geriatrics and Palliative Care Symposium brings practitioners from varying healthcare settings to develop the necessary skills to improve the quality and delivery of geriatrics and palliative care.
Didactic lectures, moderated panels, and ...
i will soon, thank you NOTICE - This message (including any attachments) may contain confidential, proprietary, privileged and/or private information. The information is intended to be for the use of the individual or entity designated above. ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com